Regulatory Toxicology and Pharmacology

Regulatory Toxicology and Pharmacology is a monthly peer-reviewed scientific journal which covers legal aspects of toxicological and pharmacological regulations. It is published by Elsevier on behalf of the International Society of Regulatory Toxicology & Pharmacology. The current co-editors-in-chief are Lesa L. Aylward and Martin van den Berg.

Regulatory Toxicology and Pharmacology

Discipline	Toxicology and pharmacology
Language	English
Edited by	Lesa L. Aylward Martin van den Berg
Publication details
History	1981–present
Publisher	Elsevier on behalf of the International Society of Toxicology & Pharmacology
Frequency	Monthly
Impact factor	3.271 (2021)
Standard abbreviations ISO 4 (alt) · Bluebook (alt) NLM (alt) · MathSciNet (alt )
ISO 4	Regul. Toxicol. Pharmacol.
Indexing CODEN (alt · alt2) · JSTOR (alt) · LCCN (alt) MIAR · NLM (alt) · Scopus · W&L
CODEN	RTOPDW
ISSN	0273-2300
LCCN	81646304
OCLC no.	485750423
Links
Journal homepage Online access

Conflicts of interest

In 2002, a group of 45 academics wrote a letter accusing the journal of a concealed pro-industry bias, a possible lack of full and independent peer review, and a failure to disclose conflicts of interest, citing a case in which Gio Batta Gori, then-current editor-in-chief, was paid $30,000 by the Tobacco Institute to write an article later published in the journal dismissing the health risks of secondhand smoke.^[1][2] The letter's coordinator later commented that the journal "reads like an industry trade publication, but it's masked as a peer-reviewed journal" and that it lacked any "credible peer-review process."^[3] In response, the journal's publisher implemented a conflict of interest disclosure policy at the journal in January 2003, shortly before the correspondence was published.^[1]

An analysis of 52 articles published in the journal about tobacco or nicotine between January 2013 and June 2015 identified that among 50 of them at least one of the authors had ties with tobacco industry. In 38 of those 50 papers, the conclusions were positive for the industry while none was negative. The two papers without any ties to the industry had conclusions negative towards the industry. The authors of the article question the confidence the scientific community can have in the journal.^[4]

Abstracting and indexing

The journal is abstracted and indexed in EMBASE, EMBiology, and Scopus.

According to the Journal Citation Reports, the journal has a 2014 impact factor of 2.031, ranking it 56th out of 87 journals in the category "Toxicology"^[5] and 146th out of 254 journals in the category "Pharmacology & pharmacy".^[6]